XML 49 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1

Business Segments (Tables)

9 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Operating and Reportable Segments

The tables below summarize information about our reportable segments.

			Three Months Ended December 31, 2024
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	238,934					$	51,383											$	290,317
Cost of sales			108,067						21,201												129,268
Gross profit			130,867						30,182												161,049
Advertising and marketing			30,995						6,950												37,945
Contribution margin			$	99,872					$	23,232											$	123,104
Other operating expenses																					31,142
Operating income																					$	91,962
* Intersegment revenues of $0.9 million were eliminated from the North American OTC Healthcare segment.

			Nine Months Ended December 31, 2024
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			711,061						$	130,183											$	841,244
Cost of sales			321,408						55,383												376,791
Gross profit			389,653						74,800												464,453
Advertising and marketing			99,637						19,082												118,719
Contribution margin			$	290,016					$	55,718											$	345,734
Other operating expenses																					97,387
Operating income																					$	248,347
* Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment.

			Three Months Ended December 31, 2023
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	236,565					$	46,176											$	282,741
Cost of sales			106,090						18,713												124,803
Gross profit			130,475						27,463												157,938
Advertising and marketing			33,917						5,549												39,466
Contribution margin			$	96,558					$	21,914											$	118,472
Other operating expenses																					31,640
Operating income																					$	86,832
* Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment.

			Nine Months Ended December 31, 2023
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	727,131					$	121,235											$	848,366
Cost of sales			323,632						52,103												375,735
Gross profit			403,499						69,132												472,631
Advertising and marketing			100,707						15,092												115,799
Contribution margin			$	302,792					$	54,040											$	356,832
Other operating expenses																					96,556
Operating income																					$	260,276
* Intersegment revenues of $2.5 million were eliminated from the North American OTC Healthcare segment.

Schedule of Revenues from Similar Product Groups

The tables below summarize information about our segment revenues from similar product groups.

			Three Months Ended December 31, 2024
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	29,314					$	1,668											$	30,982
Cough & Cold			22,984						6,347												29,331
Women's Health			53,686						4,439												58,125
Gastrointestinal			42,521						26,469												68,990
Eye & Ear Care			38,895						6,783												45,678
Dermatologicals			28,546						2,109												30,655
Oral Care			19,869						3,211												23,080
Other OTC			3,119						357												3,476
Total segment revenues			$	238,934					$	51,383											$	290,317

			Nine Months Ended December 31, 2024
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	83,472					$	4,025											$	87,497
Cough & Cold			60,999						18,304												79,303
Women's Health			158,490						14,560												173,050
Gastrointestinal			128,719						58,347												187,066
Eye & Ear Care			118,354						18,240												136,594
Dermatologicals			93,789						6,076												99,865
Oral Care			58,241						9,696												67,937
Other OTC			8,997						935												9,932
Total segment revenues			$	711,061					$	130,183											$	841,244

			Three Months Ended December 31, 2023
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	28,680					$	1,586											$	30,266
Cough & Cold			27,359						5,814												33,173
Women's Health			53,076						5,190												58,266
Gastrointestinal			38,919						22,707												61,626
Eye & Ear Care			38,503						6,569												45,072
Dermatologicals			26,603						1,165												27,768
Oral Care			20,362						3,100												23,462
Other OTC			3,063						45												3,108
Total segment revenues			$	236,565					$	46,176											$	282,741

			Nine Months Ended December 31, 2023
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	85,838					$	3,814											$	89,652
Cough & Cold			73,703						19,129												92,832
Women's Health			163,031						17,218												180,249
Gastrointestinal			122,303						49,678												171,981
Eye & Ear Care			117,719						17,715												135,434
Dermatologicals			94,299						3,972												98,271
Oral Care			61,400						9,591												70,991
Other OTC			8,838						118												8,956
Total segment revenues			$	727,131					$	121,235											$	848,366

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration